The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study)
Open accessAbstract
OBJECTIVE: The expression of vascular endothelial growth factor (VEGF) is elevated in diabetic macular edema (DME). Ranibizumab binds to and inhibits multiple VEGF variants. We investigated the safety and efficacy of ranibizumab in DME involving the foveal center. RESEARCH DESIGN AND METHODS: This was a 12-month, multicenter, sham-controlled, double-masked study with eyes (age >18 years, type 1 or 2 diabetes, central retinal thickness [CRT] ≥300 μm, and best corrected visual acuity [BCVA] of 73–39 ETDRS letters [Early Treatment Diabetic Retinopathy Study]) randomly assigned to intravitreal ranibizumab (0.3 or 0.5 mg; n = 51 each) or sham (n = 49). The treatment schedule comprised three monthly injections, after which treatment could be stopped/reinitiated with an opportunity for rescue laser photocoagulation (protocol-defined criteria). After month 1, dose-doubling was permitted (protocol-defined criteria, injection volume increased from 0.05 to 0.1 ml and remained at 0.1 ml thereafter). Efficacy (BCVA and CRT) and safety were compared between pooled ranibizumab and sham arms using the full analysis set (n = 151, patients receiving ≥1 injection). RESULTS: At month 12, mean ± SD BCVA improved from baseline by 10.3 ± 9.1 letters with ranibizumab and declined by 1.4 ± 14.2 letters with sham (P < 0.0001). Mean CRT reduction was 194.2 ± 135.1 μm with ranibizumab and 48.4 ± 153.4 μm with sham (P < 0.0001). Gain of ≥10 letters BCVA from baseline occurred in 60.8% of ranibizumab and 18.4% of sham eyes (P < 0.0001). Safety data were consistent with previous studies of intravitreal ranibizumab. CONCLUSIONS: Ranibizumab is effective in improving BCVA and is well tolerated in DME. Future clinical trials are required to confirm its long-term efficacy and safety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections
King, H., Aubert, R. E., & Herman, W. H. (1998) · Diabetes Care · doi:10.2337/diacare.21.9.1414 · Cited by 6,311
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Global data on visual impairment in the year 2002.
(2004) · Europe PMC (PubMed Central) · Cited by 4,157
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
(1985) · Archives of Ophthalmology · doi:10.1001/archopht.1985.01050120030015 · Cited by 2,540
Elman, M. J., Aiello, L. P., Beck, R. W., Bressler, N. M., Bressler, S. B., Edwards, A. R., Ferris, F. L., Friedman, S. M., Glassman, A. R., Miller, K. M., et al. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.02.031 · Cited by 1,428
The Wisconsin Epidemiologic Study of Diabetic Retinopathy
Klein, R., Klein, B. E. K., Moss, S. E., Davis, M. D., & DeMets, D. L. (1987) · Ophthalmology · doi:10.1016/s0161-6420(87)33525-0 · Cited by 1,249
Regillo, C. D., Brown, D. M., Abraham, P., Yue, H., Ianchulev, T., Schneider, S., & Shams, N. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.10.004 · Cited by 858
FERRARA, N., DAMICO, L., SHAMS, N., LOWMAN, H., & KIM, R. (2006) · Retina · doi:10.1097/01.iae.0000242842.14624.e7 · Cited by 849
The Wisconsin epidemiologic study of diabetic retinopathy: XVII
Klein, R., Klein, B. E. K., Moss, S. E., & Cruickshanks, K. J. (1998) · Ophthalmology · doi:10.1016/s0161-6420(98)91020-x · Cited by 730
Aiello, L. P., Bursell, S.-E., Clermont, A., Duh, E., Ishii, H., Takagi, C., Mori, F., Ciulla, T. A., Ways, K., Jirousek, M., et al. (1997) · Diabetes · doi:10.2337/diab.46.9.1473 · Cited by 665
(2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.06.015 · Cited by 548
A Phase II Randomized Clinical Trial of Intravitreal Bevacizumab for Diabetic Macular Edema
(2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.05.062 · Cited by 451
Abraham, P., Yue, H., & Wilson, L. (2010) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2010.04.011 · Cited by 441
ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Brown, D., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., & Kim, R. Y. (2006) · Cited by 382
Nguyen, Q. D., Shah, S. M., Heier, J. S., Do, D. V., Lim, J., Boyer, D., Abraham, P., & Campochiaro, P. A. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.04.023 · Cited by 340
Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema
Arevalo, J. F., Fromow-Guerra, J., Quiroz-Mercado, H., Sanchez, J. G., Wu, L., Maia, M., Berrocal, M. H., Solis-Vivanco, A., & Farah, M. E. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2006.12.028 · Cited by 335
Chun, D. W., Heier, J. S., Topping, T. M., Duker, J. S., & Bankert, J. M. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.04.033 · Cited by 295
Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy
Simó, R., & Hernández, C. (2008) · Diabetologia · doi:10.1007/s00125-008-0989-9 · Cited by 228
Soheilian, M., Ramezani, A., Obudi, A., Bijanzadeh, B., Salehipour, M., Yaseri, M., Ahmadieh, H., Dehghan, M. H., Azarmina, M., Moradian, S., et al. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.01.011 · Cited by 220
A randomised controlled feasibility trial of vitrectomy versus laser for diabetic macular oedema
Thomas, D., Bunce, C., Moorman, C., & Laidlaw, D. A. H. (2004) · British Journal of Ophthalmology · doi:10.1136/bjo.2004.044966 · Cited by 73
Hypoxia in the Pathogenesis of Retinal Disease
Poulaki, V. (2007) · Springer eBooks · doi:10.1007/978-3-540-29542-6_7 · Cited by 2
Cited by
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,955
Diabetic Retinopathy: Pathophysiology and Treatments
Wang, W., & Lo, A. C. Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061816 · Cited by 1,358
Mitchell, P., Bandello, F., Schmidt-Erfurth, U., Lang, G. E., Massin, P., Schlingemann, R. O., Sutter, F., Simader, C., Burian, G., Gerstner, O., et al. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.01.031 · Cited by 1,326
Self-citationThe progress in understanding and treatment of diabetic retinopathy
Stitt, A. W., Curtis, T. M., Chen, M., Medina, R. J., McKay, G. J., Jenkins, A., Gardiner, T. A., Lyons, T. J., Hammes, H.-P., Simó, R., et al. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.08.001 · Cited by 1,164
Metadata
- Authors
- Massin, P., Bandello, F., Garweg, J. G., Hansen, L. L., Harding, S. P., Larsen, M., Mitchell, P., Sharp, D., Wolf-Schnurrbusch, U. E. K., Gekkieva, M., Weichselberger, A., & Wolf, S.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-11-01
- Volume
- 33
- Issue
- 11
- Pages
- 2399-2405
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2161588304
- Cited by
- 720
- References
- 24
- FWCI
- 54.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.